S. 5571
Changes when biosimilar drugs enter Medicare price talks
Alters the timing rules for when biosimilar biological products become eligible for price negotiations under Medicare.
- Changes when biosimilar biological products can be picked for Medicare price negotiations
- Updates a part of the law that covers Medicare
In committee